We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 117

Fractured Myriad Genetics ruling follows SCOTUS remand
  • Shook Hardy & Bacon LLP
  • USA
  • August 30 2012

Ruling that one plaintiff had standing to seek a declaratory judgment as to the patent eligibility of certain genetic discoveries, the Federal Circuit Court of Appeals has once again reversed in part and affirmed in part a lower court’s determination that isolated DNA molecules and methods of comparing molecules to determine whether a patient’s genes have mutations that could cause breast and ovarian cancer were not patent eligible


Indian Supreme Court rules Novartis cancer drug change not patentable
  • Shook Hardy & Bacon LLP
  • India
  • April 4 2013

The Supreme Court of India has rejected the patent application filed by Novartis AG for a beta crystalline form of its cancer drug Gleevec, also


News Bytes - April 4, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • April 4 2013

The U.S. Food and Drug Administration (FDA) issues draft guidance titled "Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors


Court denies Myriad’s request to enjoin sale of rival BRCA1BRCA2 tests
  • Shook Hardy & Bacon LLP
  • USA
  • March 20 2014

A federal court in Utah has denied the request for a preliminary injunc- tion filed by Myriad Genetics against a rival company that offered tests


News Bytes
  • Shook Hardy & Bacon LLP
  • USA
  • February 27 2014

The U.S. Food and Drug Administration requests comments on the estimated time burdens of a proposed study that "will investigate the impact of


Ambry Genetics countersues Myriad Genetics in genetic patent infringement suit
  • Shook Hardy & Bacon LLP
  • USA
  • August 15 2013

Responding to the patent infringement claims asserted against it by Myriad Genetics, Ambry Genetics Corp. denies that the 15 patents at issue were


News Bytes - April 18, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

The U.S. Department of Commerce announces the winners of the U.S. Patent and Trademark Office's Patents for Humanity pilot program. The awards


News Bytes
  • Shook Hardy & Bacon LLP
  • USA
  • February 13 2014

The U.S. Patent and Trademark Office requests comments by March 3, 2014, on the revision of a previously approved information collec- tion concerning


News bytes 10 January 2013
  • Shook Hardy & Bacon LLP
  • USA
  • January 10 2013

The U.S. Patent and Trademark Office (USPTO) schedules an Additive Manufacturing Partnership Meeting on January 23, 2013, at its Alexandria, Virginia


NGOs request march-in rights for patented drug
  • Shook Hardy & Bacon LLP
  • USA
  • November 1 2012

Four non-governmental organizations (NGOs) have filed a petition with the National Institutes of Health (NIH) requesting that it grant march-in rights under the Bayh-Dole Act for a patented drug that they claim is “a federally funded invention that is much more expensive in the United States than in Canada, Europe or other high-income countries.”